Effect of statins on soluble CD40 liqand in hypercholesterolemia type 2 diabetic patients

Journal of Endocrinological Investigation

Volumn 31, Issue 7, 2008, Pages 660-665

  Santini, E ^a   Madec, S ^a   Corretti, V ^a   Ferrannini, E ^a   Solini, A ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

CD40 ligand; Cholesterol; Inflammation; Stacin; Type 2 diabetes

Indexed keywords

ALBUMIN; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CD40 LIGAND; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N ACETYL BETA GLUCOSAMINIDASE; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; RISK REDUCTION; SHORT COURSE THERAPY; SYSTOLIC BLOOD PRESSURE;

EID: 54949089609     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345621     Document Type: Article

References (39)

1. Kakafika AI, Liberopoulos EN, Karagiannis A, Athyros VG, Mikhailidis DP. Dyslipidaemia, hypercoagulability and the metabolic syndrome. Curr Vasc Pharmacol 2006, 4: 175-83.
2. Sobel BE, Schneider DJ. Platelet function, coagulopathy, and impaired fibrinolysis in diabetes. Cardiol Clin 2004, 22: 511-26.
3. Grundy SM. Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. Clin Cornerstone 2006, 8 (Suppl 1): S21-7.
4. Sjöholm A, Nyström T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev 2006, 22: 4-10.
5. Schönbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001, 58: 4-43.
6. Garlichs CD, Eskafi S, Raaz D, et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001, 86: 649-55.
7. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003, 348: 1104-11.
8. Varo N, de Lemos JA, Libby P, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003, 108: 1049-52.
9. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101: 1767-72.
10. Ridker PM, Willerson JT. Inflammation as a cardiovascular risk factor. Circulation 2004, 109: II2-10.
11. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006, 166: 2307-13.
12. Pleiner J, Schaller G, Mittermayer F, et al. Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 2004, 110: 3349-54.
13. Endres M. Statins: potential new indications in inflammatory conditions. Atheroscler Suppl 2006, 7: 31-5.
14. Arnaud C, Burger F, Steffens S, et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol 2005, 25: 1231-6.
15. Sanguigni V, Pignatelli P, Lenti L, et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005, 111: 412-9.
16. Koh KK, Quon MJ, Han SH, Ahn JY, Lee Y, Shin EK. Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes. Atherosclerosis 2007, 194: 230-7.
17. Bláha V, Andrys C, Smahelová A, et al. Effect of atorvastatin on soluble CD14, CD40 Ligand, sE- and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus: relationship to cholesterol turnover. Pharmacol Res 2006, 54: 421-8.
18. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987, 442: 43-52.
19. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103: 926-33.
20. Joukhadar C, Klein N, Prinz M, et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 2001, 85: 47-51.
21. Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has anti-inflammatory and anti-atherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001, 21: 115-21.
22. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methyl-glutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21: 1712-9.
23. Han SH, Koh KK, Quon MJ, Lee Y, Shin EK. The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. Atherosclerosis 2007, 190: 205-11.
24. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007, 49: 554-61.
25. Marketou ME, Zacharis EA, Nikitovic D, et al. Early effects of simvastatin versus atorvastatin on oxidative stress and proinflammatory cytokines in hyperlipidemic subjects. Angiology 2006, 57: 211-8.
26. Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 2004, 109: 2524-8.
27. Schonbeck U, Mach F, Libby P. CD154 (CD40 ligand). Int J Biochem Cell Biol 2000, 32: 687-93.
28. Schöbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as anti-inflammatory agents? Circulation 2004, 109 (Suppl 1): II18-26.
29. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001, 286: 64-70.
30. Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol 2007, 99: 1706-13.
31. Hernandez TL, Capell WH, Wolfe P, Gerard LA, Eckel RH. Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus. Am J Cardiol 2006, 98: 1656-9.
32. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 2006, 97: 33A-41A.
33. Milionis HJ, Papakostas J, Kakafika A, Chasiotis G, Seferiadis K, Elisaf MS. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol 2003, 43: 825-30.
34. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004, 94: 157-61.
35. Tonolo G, Velussi M, Brocco E, et al. Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney Int 2006, 70: 177-86.
36. Mooradian AD, Haas MJ. Statins ameliorate glomerular permeability changes in streptozotocin-induced diabetic rats. Am J Ther 2007, 14: 41-5.
37. Uslu S, Efe B, Alatas O, et al. Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients. J Nephrol 2005, 18: 559-67.
38. Rogers SL, Magliano DJ, Levison DB, et al. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. Clin Ther 2007, 29: 242-52.
39. Yan JC, Ma GS, Wu ZG, Kong XT, Zong RQ, Zhan LZ. Increased levels of CD40-CD40 ligand system in patients with essential hypertension. Clin Chim Acta 2005, 355: 191-6.